The European Medicines Agency (EMA) has published terms and conditions for its public Application Programming Interface (API) for the Product Management Service (PMS), allowing users to access medicinal product data from multiple EU sources. The document, dated 12 June 2026, outlines that the API is currently in beta release and should not be used for business purposes, with EMA reserving the right to modify or restrict access without prior notice.
The PMS public API provides data compiled from the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD), the SIAMED database for centrally authorised products, and direct stakeholder submissions. EMA notes that data may have undergone technical processing, transformation, harmonisation, or mapping, with details available in the European Union Implementation Guide (EU IG), Chapters 3, 7, and 9. Confidential data is removed per Annex A of Chapter 5 of the EU IG.
Users must agree to EMA's API General Terms and Conditions of Use. The agency emphasises that the medicinal product information is for reference only, not formally validated by National Competent Authorities, and may differ from national records. In case of discrepancies, the relevant authority's records prevail.
During the beta phase, users can explore the API for familiarisation, testing, and analytical exploration, but not for business purposes. EMA may evolve the API's functionality, scope, structure, and content. After transition to production, prior authorisation will be required to sell, sublicence, incorporate, or redistribute the content.
EMA provides the API to enhance public access to information on medicines. If erroneous or incomplete data is reported via EMA ServiceNow, EMA will evaluate and take appropriate measures, but accepts no responsibility or liability for any loss or damage arising from API use.
The API benefits researchers, developers, and public health analysts by providing centralised access to medicinal product data. However, the beta status and non-business-use restriction limit immediate commercial applications. Pharmaceutical companies and marketing authorisation holders may need to ensure their data submissions are accurate, as discrepancies could affect public data. National competent authorities may face questions about data consistency between PMS and national records. The terms also protect EMA from liability, shifting responsibility to users for verifying data accuracy.